Market outlook of the global gastric cancer drugs market
Technavios market research analyst predicts the global gastric cancer drugs market to grow rapidly at a CAGR of approximately 8% during the forecast period. The presence of huge unmet needs in the market is expected to result in this markets healthy growth during the forecast period. The presence of this high-unmet medical need will lead to an increased R&D of safe and effective drugs, which in turn will spur market growth during the estimated period.
The recent increase in the prevalence of gastric cancer due to lifestyle changes is expected to drive market growth. The sedentary lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity are envisaged to result in the increased incidence of gastric cancer.
Geographical segmentation and analysis of the gastric cancer drugs market
• Americas
• APAC
• Europe
In this market study, analysts have estimated the APAC region to account for the highest market share during the forecast period. Much of this regions growth can be attributed to the increasing demand for better healthcare infrastructure, which results in its massive market share of nearly 48% during the forecast period.
Competitive landscape and key vendors
The global gastric cancer drugs market is growing rapidly owing to the high proportion of individuals with gastric cancer and the presence of a strong drug pipeline. To gain traction in this market, the vendors are manufacturing and marketing gastric cancer drugs that exhibit a high safety and efficacy profile, this helps the vendors to gain a competitive edge over their peers.
The top vendors in the market are -
• Hoffmann-La Roche
• Eli-lilly
• Sanofi
• Otsuka Holdings
Other prominent vendors in the market include Novartis, Amgen, Boston Biomedical, AROG Pharmaceuticals, ARIAD Pharmaceuticals, Roche, Merck, Eli Lilly, AB Science, Galena Biopharma, AstraZeneca, Taiho Oncology, Samumed, Ipsen Biopharmaceuticals, Eddingpharm, Tekmira Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, ASLAN Pharmaceuticals, Five Prime, Array Biopharma, BIND Therapeutics, Boehringer Ingelheim, Daiichi-Sankyo, Bayer HealthCare, and Celgene.
Key questions answered in the report include
• What will the market size and the growth rate be in 2020?
• What are the key factors driving the global gastric cancer drugs market?
• What are the key market trends impacting the growth of the gastric cancer drugs market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the vendors in the global gastric cancer drugs market?
• Trending factors influencing the market shares of the Americas, APAC, and Europe?
• What are the key outcomes of the five forces analysis of the gastric cancer drugs market?
Technavio also offers customization on reports based on specific client requirement.
Related report:
• Global Colorectal Cancer Drugs Market 2015-2019
• Global Colorectal Cancer Drugs Market 2015-2019
• Global Cancer Pain Therapeutics Market 2015-2019
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
PART 05: Disease overview
Understanding the disease
Pathophysiology
Causes
Signs and symptoms
Diagnosis
Staging
Japanese staging system
Treatment
Epidemiology
Economic burden
PART 06: Pipeline portfolio
Information on pipeline candidates
PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 08: Market segmentation by molecule type
Small molecules
Biologics
PART 09: Market segmentation by route of administration
Oral
Parenteral
PART 10: Market segmentation by lines of chemotherapy
First-line chemotherapy
Second-line chemotherapy
PART 11: Geographical segmentation
Global gastric cancer drugs market by geographical segmentation 2015-2020
Gastric cancer drugs market in APAC
Gastric cancer drugs market in Japan
Gastric cancer drugs market in China
Gastric cancer drugs market in Americas
Gastric cancer drugs market in EMEA
PART 12: Market drivers
Promising drug pipeline
Unmet medical needs
Increase in patient population
Patient assistance programs
PART 13: Impact of drivers
PART 14: Market challenges
High cost of drugs
Adverse side effects
Shortage of drugs
Delayed diagnosis
PART 15: Impact of drivers and challenges
PART 16: Market trends
Rise in public awareness
Use of off-label drugs
Intense competition among vendors
PART 17: Vendor landscape
Competitive scenario
Market share analysis 2015
Eli Lilly
PART 18: Key vendor analysis
Eli Lilly
F. Hoffmann-La Roche
Otsuka Holdings
Sanofi
Other prominent vendors
PART 19: Appendix
List of abbreviation
PART 20: Explore Technavio
Exhibit 01: Product offerings 9
Exhibit 02: Types of gastric cancer
Exhibit 03: Frequency of different types of gastric cancers
Exhibit 04: Causes of gastric cancer
Exhibit 05: Signs and symptoms of gastric cancer
Exhibit 06: Diagnostic tests for gastric cancer
Exhibit 07: Staging of gastric cancer
Exhibit 08: Treatment options for gastric cancer
Exhibit 09: First-line therapy for metastatic or locally advanced gastric cancer
Exhibit 10: Second-line therapy for gastric cancer
Exhibit 11: Surgeries for gastric cancer
Exhibit 12: Types of radiation therapy for gastric cancer
Exhibit 13: Estimated number of new cancers (all ages) males and females in Americas, EMEA, and APAC: 2015 and 2020
Exhibit 14: Estimated number of new cancers (age <65 and >=65) males and females in Americas, EMEA, and APAC: 2015
Exhibit 15: Estimated number of mortality cases (all ages) males and females in Americas, EMEA, and APAC: 2015
Exhibit 16: Estimated number of mortality cases (age <65 and >=65) males and females in Americas, EMEA, and APAC: 2015
Exhibit 17: Pipeline molecules for gastric cancer
Exhibit 18: Gastric cancer clinical trials by development phase
Exhibit 19: Gastric cancer clinical trials by trial status
Exhibit 20: Global gastric cancer drugs market 2015-2020 ($ millions)
Exhibit 21: Five forces analysis
Exhibit 22: Global gastric cancer drugs market segmented by molecule type
Exhibit 23: Global gastric cancer drugs market segmented by route of administration
Exhibit 24: Dose and administration schedule of Teysuno (S-1) plus cisplatin
Exhibit 25: Lines of therapy for the treatment of advanced gastric cancer
Exhibit 26: Estimated annual cost per patient for chemotherapy regimen in EU ($ millions)
Exhibit 27: Global gastric cancer drugs market by geographical segmentation 2015
Exhibit 28: Global gastric cancer drugs market region wise 2015-2020 ($ millions)
Exhibit 29: Gastric cancer drugs market in APAC 2015-2020 ($ millions)
Exhibit 30: Gastric cancer drugs market in Japan 2015-2020 ($ millions)
Exhibit 31: Gastric cancer drugs market in China 2015-2020 ($ millions)
Exhibit 32: Gastric cancer drugs market in Japan and China 2015-2020 ($ millions)
Exhibit 33: Gastric cancer drugs market in Americas 2015-2020 ($ millions)
Exhibit 34: Gastric cancer drugs market in EMEA 2015-2020 ($ millions)
Exhibit 35: Key drivers for global gastric cancer drugs market
Exhibit 36: Number of patients treated with Herceptin via Patient Assistance Program in China
Exhibit 37: Impact of drivers
Exhibit 38: Challenges of global gastric cancer drugs market
Exhibit 39: Average cost comparison of Herceptin
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Trends of global gastric cancer drugs market
Exhibit 42: Timeline of Cyramza in US, EU, and Japan
Exhibit 43: Eli Lilly: Key takeaways
Exhibit 44: Timeline of Herceptin in US, EU, and Japan
Exhibit 45: F. Hoffmann-La Roche: Global YoY growth and revenue of Herceptin 2011-2014 ($ millions)
Exhibit 46: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in US 2013-2014 ($ millions)
Exhibit 47: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in EU 2013-2014 ($ millions)
Exhibit 48: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in Japan 2013-2014 ($ millions)
Exhibit 49: F. Hoffmann-La Roche: Key takeaways
Exhibit 50: Timeline of Tegafur in Japan, EU, and Asia
Exhibit 51: Otsuka Holdings: Key takeaways
Exhibit 52: Timeline of Taxotere in US, EU, and Japan
Exhibit 53: Sanofi: Global YoY growth and revenue of Taxotere 2011-2014 ($ millions)
Exhibit 54: Sanofi: YoY growth and revenue of Taxotere in US 2011-2014 ($ millions)
Exhibit 55: Sanofi: YoY growth and revenue of Taxotere in EU 2011-2014 ($ millions)
Exhibit 56: Sanofi: Key takeaways
Exhibit 57: Eli Lilly: Business segmentation by revenue 2014
Exhibit 58: Eli Lily: Business/Product segmentation by revenue 2012 and 2013 ($ millions)
Exhibit 59: Eli Lily: Geographical segmentation by revenue 2014
Exhibit 60: F. Hoffmann-La Roche: Business segmentation by revenue 2014
Exhibit 61: F. Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 62: F. Hoffmann-La Roche: Geographical segmentation by revenue 2014
Exhibit 63: Otsuka Holdings: Business segmentation 2014 by revenue
Exhibit 64: Otsuka Holdings: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 65: Otsuka Holdings: Geographical segmentation by revenue 2014
Exhibit 66: Sanofi: Business segmentation by revenue 2014
Exhibit 67: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 68: Sanofi: Geographical segmentation by revenue 2014
